Jason B. Cross
Computational Chemistry & Drug Discovery · 2009–2023
A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Computational Chemistry & Drug Discovery — 7 citations into it
Whom Jason B. Cross trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Anthony Nicholls
- Hans-Joachim Böhm
- Brian K. Shoichet
- Ruben Abagyan
- Richard A. Friesner
- Niu Huang
- Ajay N. Jain
- Christopher W. Murray
- Jason C. Cole
- Irwin D. Kuntz
Who trusts Jason B. Cross overall
Papers from Jason B. Cross's perspective
Ordered by how strongly the researchers Jason B. Cross trusts endorse each paper. Same corpus, a different order for every researcher.
- Benchmarking sets for molecular docking.
- Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.
- Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem
- Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes
- Development and validation of a modular, extensible docking program: DOCK 5 (J. Comput. Aided Mol. Des.)
- Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. (Journal of Medicinal Chemistry)
- Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.
- Comparison of Topological, Shape, and Docking Methods in Virtual Screening (Journal of Chemical Information and Modeling)
- Molecular docking using shape descriptors
- Recommendations for evaluation of computational methods
Their papers
- Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy (2009) — 443 citations
- An inhibitor of oxidative phosphorylation exploits cancer vulnerability (2018) — 808 citations
- Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy. (2023) — 20 citations